SP-624
DrugOral Capsule
NCT Number: NCT04510298
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Collaborative Neuroscience Research, Garden Grove, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Oral Capsule
Oral Capsule
Time frame: Up to 8 weeks
Time frame: Up to 4 weeks
chemistry, hematology, and urinalysis tests will be performed
Time frame: Up to 4 weeks
Blood pressure is measured by sphygmomanometer. Change from baseline measurement will be calculated
Time frame: Up to 4 weeks
Pulse rate is measured by sphygmomanometer. Change from baseline measurement will be calculated
Time frame: Up to 4 weeks
Body temperature is measured by oral thermometer. Change from baseline measurement will be calculated
Time frame: Up to 4 weeks
Body weight is measured by weight scale. Measurement is reported in kilograms. Change from Baseline measurement will be calculated.
Time frame: Up to 4 weeks
Heart rate is measured by 12-lead electrocardiogram (ECG). Change from Baseline measure will be calculated.
Time frame: Up to 4 weeks
RR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Time frame: Up to 4 weeks
PR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Time frame: Up to 4 weeks
QTcF is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.
Time frame: Up to 4 weeks
Time frame: Up to 5 weeks
Treatment-emergent suicidal ideation and/or behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments
Time frame: Up to 4 weeks
Treatment-emergent abnormal movements will be assessed using a battery of movement assessments
Sirtsei Pharmaceuticals, Inc.
Industry
A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05838573
Cognition Disorders, Cognitive Dysfunction
Changsha, Hunan, China
View Trial DetailsNCT05304767
Mental Disorders, Schizophrenia
Phoenix, Arizona, United States
View Trial DetailsNCT00004571
Mental Disorders, Normal Physiology
Bethesda, Maryland, United States
View Trial DetailsNCT05808244
Mental Disorders, Psychosis
Kowloon, Hong Kong
View Trial Details